Orchid gets milestone from AstraZeneca

28 June 2001

Orchid BioSciences of the USA says that it has successfully completedthe first milestone in its multi-year genotyping and pharmacogenetics collaboration with AstraZeneca, resulting in "a significant payment." Financial details were not disclosed.

Using the SNPcode technology that combines Orchid's proprietary SNP-IT biochemistries with the GenFlex chip and GeneChip system of Affymetrix, the former claims to have rapidly developed assays and conducted genotyping for the first cohort of samples provided by AstraZeneca. Jack Ball, senior vice president and general manager of Orchid's Life Sciences Group, said: "we are achieving outstanding accuracy and throughput on the high throughput SNPcode platform that we recently added to our MegaSNPatron genotyping facility," adding that these results "are further confirmation of the exceptional performance of this system."

Rakesh Anand, director of R&D genetics, enabling science and technology at AstraZeneca, said the firm is "very happy with the quality of the data that Orchid has delivered in the first phase of this effort as well as the overall spirit of the collaboration." The pact was signed in February 2001, and includes the design and development of SNP panels and assays for a variety of disease areas and analyses to support pharmacogenetics studies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight